{"study_name":"Study from Banna 2022.pdf","extracted_data":{"results":{"pembrolizumab plus platinum-based chemotherapy":{"os_12_month":"52.2%","group_difference":"Patients with high NLR (â‰¥4) had significantly shorter OS (median 11.8 vs 14.9 months, p=0.02) and PFS (median 6.6 vs 9.0 months, p=0.018) than those with low values.","median_os":"12.7 months","median_rw_pfs":"8.0 months"}},"study_name":"Study from Banna 2022.pdf","file_name":"Banna 2022.pdf","treatment_regimens":["pembrolizumab plus platinum-based chemotherapy"],"countries":["United Kingdom","Switzerland"],"populations":[{"pdl1_status":"Negative","n":164,"stage, histology":"IIIB/IVA, Adenocarcinoma"},{"stage, histology":"IVB, Adenocarcinoma","pdl1_status":"Negative","n":113},{"stage, histology":"IIIB/IVA, Squamous","pdl1_status":"Negative","n":51},{"pdl1_status":"Negative","n":0,"stage, histology":"IVB, Squamous"},{"stage, histology":"IIIB/IVA, Other","pdl1_status":"Negative","n":11},{"pdl1_status":"Negative","n":0,"stage, histology":"IVB, Other"}]},"status":"success","_wandb":{"runtime":10},"_timestamp":1.742677794577763e+09,"_runtime":10.358427,"_step":0}